Acute Myeloid Leukemia | Topics

 
Pre-HSCT WT1 Levels Vs ELN 2017 Risk Classification Is a Better Predictor of Outcomes in Intermediate-Risk AML
July 20, 2022

Although European Leukemia Net 2017 Risk Stratification was ineffective for predicting outcomes following allogeneic hematopoietic stem cell transplantation in intermediate-risk acute myeloid leukemia, pre-transplant Wilms tumor gene 1 expression and FLT3-ITD mutation demonstrated promising predictive ability.

Black Adolescent Young Adults With AML Have Worse Outcomes Vs White Population
July 08, 2022

Black adolescent young adult patients with acute myeloid leukemia appeared to have inferior outcomes compared with White patients.

Similar OS and Transplantation Observed With Decitabine vs Chemo in Geriatric AML
June 20, 2022

Older patients with acute myeloid leukemia who were treated with decitabine experienced comparable outcomes vs daunorubicin and cytarabine.

Quizartinib Added to Chemo Boosts Overall Survival in FLT3-ITD–positive AML
June 13, 2022

The combination of quizartinib plus chemotherapy yielded better survival outcomes vs chemotherapy alone in the frontline setting of FLT3-ITD-positive acute myeloid leukemia.

Ivosidenib Plus Azacitidine Yields Significant Treatment Benefit in IDH1-Mutant AML
June 04, 2022

Results from the phase 3 AGILE study show patients with IDH1-mutant acute myeloid leukemia had improved outcomes when treated with ivosidenib plus azacitidine vs placebo plus azacitidine.

Manageable Anemia Achieved With Magrolimab Plus Azacitidine in High-Risk MDS/AML
June 04, 2022

Combining magrolimab with azacitidine led to manageable anemia in patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia.

Uday R. Popat, MD, on the Future of Post-Transplant Cyclophosphamide to Prevent GVHD After Transplant for AML/MDS
May 27, 2022

Uday R. Popat, MD, spoke about where he sees future research efforts headed regarding post-transplant cyclophosphamide to prevent graft-vs-host disease for patients with acute myeloid leukemia after transplant and how these results could impact the standard of care.

FDA Expands Approval of Ivosidenib and Azacitidine for IDH1-Mutant Newly Diagnosed AML
May 25, 2022

Patients with acute myeloid leukemia who are 75 years or older or ineligible for induction chemotherapy due to comorbidities can now receive treatment with ivosidenib and azacitidine.

Polygenic Score May Offer Personalized Treatment Options for Pediatric AML
May 18, 2022

Investigators used a patient-specific score to predict treatment outcomes in pediatric patients with acute myeloid leukemia, allowing them to identify who may benefit from higher-dose chemotherapy.

Adolescent and Young Adult ALL and AML Survivors Exhibit Worse Long-Term Survival vs General Population
May 13, 2022

Leukemia survivors who were adolescents or young adults had worse long-term survival outcomes vs the general population.